Available in Brazil
This is a multinational, multicenter, double-blind, placebo-controlled study in
approximately 50 participants, who will be randomized 1:1 to receive a single infusion of
either nexiguran ziclumeran or placebo. To ensure all participants will have the
potential to receive nexiguran ziclumeran, participants will have the option to cross
over to the opposite study arm at Month 12 or Month 18, depending on study criteria.
50Patients around the world